AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy
AbbVie’s immunology team is tossing $60 million into the pot being wagered on the lead drug at Mitch Gold’s latest venture.
The Dendreon founder …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
